Natural anti inflammatory supplements Curcumin

Turmeric and Curcumin has been shown to have a wide spectrum of biological actions.
Its anticancer effect is mainly mediated through induction of apoptosis.

 Clinically, curcumin has already been used to reduce post-operative inflammation.
Safety evaluation studies indicate that both turmeric and curcumin are well tolerated at
 very high dose without any toxic effects.

Thus, both turmeric and curcumin have the potential for the development of modern medicine for the treatment of various diseases.

Inflammatory diseases
Health benefits of Turmeric and Curcumin capsules

A preliminary intervention trial that compared curcumin with a nonsteroidal anti-inflammatory drug (NSAID) in 18 rheumatoid arthritis patients found that improvements in morning stiffness, walking time, and joint swelling after two weeks of curcumin supplementation (1,200 mg/day) were comparable to those experienced after two weeks of phenylbutazone (NSAID) therapy (300 mg/day) . A placebo-controlled trial in 40 men who had surgery to repair an inguinal hernia or hydrocele found that oral curcumin supplementation (1,200 mg/day) for five days was more effective than placebo in reducing post-surgical edema, tenderness and pain, and was comparable to phenylbutazone therapy (300 mg/day). Two uncontrolled studies found that oral curcumin (1,125 mg/day) for 12 weeks or longer improved anterior uveitis and idiopathic inflammatory orbital pseudotumor, two inflammatory conditions of the eye. However, without a control group, it is difficult to draw conclusions regarding the anti-inflammatory effects of curcumin in these conditions. Larger randomized controlled trials are needed to determine whether oral curcumin supplementation is effective in the treatment of inflammatory diseases, such as rheumatoid arthritis.

Curcumin and inflammatory bowel disease (IBD)

One of the common uses of Curcumin is the complementary treatment of inflammatory bowel disease, Crohn's disease and colitis (ulcerative colitis).

These diseases are becoming increasingly common in recent years in the Western world.

Statistics show that in Europe and the United States,there are tens of thousands of patients diagnosed with bowel diseases Inflammation such as Crohn's disease and ulcerative colitis. These are complex chronic diseases

Involving serious infections throughout the digestive tract, mainly the intestines, causing diarrhea, Abdominal pain, bleeding ports, weight loss, anemia, Children 's growth disorders and significant impairment in their quality of life.

Clinical research about the benefits of curcumin has shown that giving curcumin led 

to an improvement in patient's medical state  and a reduction in medication dose.

 

The conclusion of the researchers was that the compound has a possitive effect

on treatment for patients suffering from IBD, and has shown an improvement in the  Colon's mucosal
in endoscopic examination and can prevent the return of seizures

 

Turmeric and Curcumin health studies:

  1. http://www.ncbi.nlm.nih.gov/pubmed/17101300

  2. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701433/

  3. Indian J Pharmacol. 2015 Mar-Apr;47(2):160-6. doi: 10.4103/0253-7613.153422. Exploring the role of curcumin containing ethanolic extract obtained from Curcuma longa (rhizomes) against retardation of wound healing process by aspirin. Pawar RS1, Toppo FA1, Mandloi AS1, Shaikh S1.

  4. J Mol Cell Cardiol. 2015 Feb;79:1-12. doi: 10.1016/j.yjmcc.2014.10.002. Epub 2014 Oct 16. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo.

  5. Harefuah. 2015 Jan;154(1):56-8, 66. Curcumin add-on therapy for ulcerative colitis.

  6. Otol Neurotol. 2014 Jun;35(5):e169-77. Curcuma longa (curcumin) decreases in vivo cisplatin-induced ototoxicity through heme oxygenase-1 induction.Fetoni AR1, Eramo SL, Paciello F, Rolesi R, Podda MV, Troiani D, Paludetti G.

  7. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21, 2895–2900.

  8. Ricky A. Sharma, Stephanie A. Euden, et al.  Phase I Clinical Trial of Oral Curcumin  Biomarkers of Systemic Activity and Compliance . Clinical Cancer Research  2004, 10, 6847-6854

  9. 2011 Nov;14(6):588-97. Curcuma as a functional food in the control

  10.  of cancer and inflammation.Schaffer M1, Schaffer PM, Zidan J, Bar Sela G

All written in this site, including health benefit statements has not been evaluated by the united states Food and Drug Administration. These products which are presented in this web site, are not intended to diagnose, treat, cure, or prevent any disease. Iyar herbals ltd. read more about this